Apimeds Pharmaceuticals US, Inc. plans to list on the NYSE American under the symbol APUS. It filed a Form S-1 registration statement for an initial public offering on September 25, 2024. As of November 6, 2026, its final prospectus is on file (Form 424B4, May 9, 2025).
Sell to companies like Apimeds Pharmaceuticals US, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Key facts
Apimeds Pharmaceuticals US, Inc. filed a Form S-1 registration statement for an initial public offering on 2024-09-25. It has amended it 7 times. It filed its final prospectus on 2025-05-09. Each fact below is quoted from the filing named with it.
Also on the record for Apimeds Pharmaceuticals US, Inc.
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| October 1, 2026 | Leadership change: Erick Frim departs, Chief Financial Officer, and 2 more | — | Leadership changes | Source |
| May 7, 2026 | Stake report, Schedule 13D/A, by Inscobee Inc. | 34.3% of the class | 5%+ stakes | Source |
| May 5, 2026 | Leadership change: Sungjoon Chae appointed, Chief Executive Officer | — | Leadership changes | Source |
| May 4, 2026 | Leadership change filing (Form 8-K, Item 5.02) | — | Leadership changes | Source |
| April 9, 2026 | Leadership change filing (Form 8-K, Item 5.02) | — | Leadership changes | Source |
| March 30, 2026 | Stake report, Schedule 13D/A, by Inscobee Inc. | 34.3% of the class | 5%+ stakes | Source |
| March 20, 2026 | Stake report, Schedule 13D/A, by Inscobee Inc. | 34.3% of the class | 5%+ stakes | Source |
| February 11, 2026 | Stake report, Schedule 13G, by Ayrton Capital LLC | 9.99% of the class | 5%+ stakes | Source |
| January 26, 2026 | Stake report, Schedule 13D/A, by Inscobee Inc. | 34.3% of the class | 5%+ stakes | Source |
Check before you invest in Apimeds Pharmaceuticals US, Inc.: the warning signs and who's behind it, free.
Free to see. No signup.
Keep reading
More on Apimeds Pharmaceuticals US, Inc. and the records around it.
Apimeds Pharmaceuticals US, Inc. elsewhere on the record
- 5%+ stake filings May 2026
- Who owns it
Companies that share a holder
- Ayrton Capital LLC also filed stake reports on 31 other companies: Bluejay Diagnostics, Inc. (Aug 2026), BTC Digital Ltd. (Aug 2026), DEFSEC Technologies Inc. (Aug 2026)
Also filing to list on the NYSE American
IPO filings on the NYSE American in Q2 2025, newest first.
- Volato Group, Inc. (May 2025)
Watch Apimeds Pharmaceuticals US, Inc.
Get an email when Apimeds Pharmaceuticals US, Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Apimeds Pharmaceuticals US, Inc.?
Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)
A Full Report on Apimeds Pharmaceuticals US, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Apimeds Pharmaceuticals US, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
18 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
What the filings say
Listing
Our common stock has been approved for listing on the NYSE American (the “NYSE American”) under the symbol “APUS.”From the 424B4 filed 2025-05-09
Use of proceeds
We intend to use the net proceeds we receive from this offering to fund our Phase III clinical trial in knee OA, to initiate at least one non -registered company sponsored trials in MS, manufacturing costs, to repay current debt liabilities, and any remaining amounts to fund working capital and general corporate purposes.From the 424B4 filed 2025-05-09
Revenue
Our company will remain an SRC until the last day of the fiscal year in which it had (i) a public float that exceeded $250 million or (ii) annual revenues of more than $100 million and a public float that exceeded $700 million.From the S-1/A filed 2025-02-10
Net loss or income
Our net losses were $1,078,357 and $210,728 for the nine months ended September 30, 2024 and 2023, respectively.From the S-1/A filed 2025-02-10
Timeline
| Filed | What it is | Filing |
|---|---|---|
| 2024-09-25 | Registration statement filed | S-1 |
| 2024-11-08 | Registration statement amended | S-1/A |
| 2024-12-09 | Registration statement amended | S-1/A |
| 2024-12-20 | Registration statement amended | S-1/A |
| 2025-01-10 | Registration statement amended | S-1/A |
| 2025-01-29 | Registration statement amended | S-1/A |
| 2025-02-06 | Registration statement amended | S-1/A |
| 2025-02-10 | Registration statement amended | S-1/A |
| 2025-05-09 | Final prospectus filed: the offering is priced | 424B4 |
Tools for this story
Each opens in a new tab, filled in for Apimeds Pharmaceuticals US, Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
A company that wants to sell shares to the public in the United States files a registration statement with the SEC: Form S-1 for a US company, Form F-1 for a foreign one. It amends that statement as the figures and terms are filled in, usually adding the expected price range shortly before the offering. Once the offering is priced it files its final prospectus under Rule 424(b)(4). A company that decides not to go ahead can ask for the registration statement to be withdrawn on Form RW.
Every row on this page is one of those filings, linked to the filing itself. The facts are the company's own sentences, quoted from the filing named beside each one and never reworded; where no filing states a fact in a sentence that can be read exactly, this page leaves it out. A filing is the company's statement of its plans and its figures, not a verification of them, and nothing here is investment advice.